Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant in Combination Therapies for ER+/HER2- Metastatic Breast Cancer
NCT05563220Phase 2Active, not recruiting
- Sponsor
- Stemline Therapeutics
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Molecular Glues
- Countries
- 13
01
Overview
Phase 2, open-label trial of elacestrant in breast cancer (5 arms), sponsored by Stemline Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 28 days and Progression-Free Survival at 6 months. Started Jan 2023; status: active, not recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05563220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05563220.